Prostate cancer, version 2.2019

James L. Mohler; Emmanuel S. Antonarakis; Andrew J. Armstrong; Anthony V. D'Amico; Brian J. Davis; Tanya Dorff; James A. Eastham; Charles A. Enke; Thomas A. Farrington; Celestia S. Higano; Eric Mark Horwitz; Michael Hurwitz; Joseph E. Ippolito; Christopher J. Kane; Michael R. Kuettel; Joshua M. Lang; Jesse McKenney; George Netto; David F. Penson; Elizabeth R. Plimack; Julio M. Pow-Sang; Thomas J. Pugh; Sylvia Richey; MacK Roach; Stan Rosenfeld; Edward Schaeffer; Ahmad Shabsigh; Eric J. Small; Daniel E. Spratt; Sandy Srinivas; Jonathan Tward; Dorothy A. Shead; Deborah A. Freedman-Cass

doi:10.6004/jnccn.2019.0023

Prostate cancer, version 2.2019

James L. Mohler, Emmanuel S. Antonarakis, Andrew J. Armstrong, Anthony V. D'Amico, Brian J. Davis, Tanya Dorff, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Michael Hurwitz, Joseph E. Ippolito, Christopher J. Kane, Michael R. Kuettel, Joshua M. Lang, Jesse McKenney, George Netto, David F. Penson, Elizabeth R. PlimackJulio M. Pow-Sang, Thomas J. Pugh, Sylvia Richey, MacK Roach, Stan Rosenfeld, Edward Schaeffer, Ahmad Shabsigh, Eric J. Small, Daniel E. Spratt, Sandy Srinivas, Jonathan Tward, Dorothy A. Shead, Deborah A. Freedman-Cass

Research output: Contribution to journal › Article › peer-review

992 Scopus citations

Abstract

The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced disease for clinicians who treat patients with prostate cancer. The portions of the guidelines included herein focus on the roles of germline and somatic genetic testing, risk stratification with nomograms and tumor multigene molecular testing, androgen deprivation therapy, secondary hormonal therapy, chemotherapy, and immunotherapy in patients with prostate cancer.

Original language	English
Pages (from-to)	479-505
Number of pages	27
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	17
Issue number	5
DOIs	https://doi.org/10.6004/jnccn.2019.0023
State	Published - 2019

Access to Document

10.6004/jnccn.2019.0023

Cite this

Mohler, J. L., Antonarakis, E. S., Armstrong, A. J., D'Amico, A. V., Davis, B. J., Dorff, T., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., Horwitz, E. M., Hurwitz, M., Ippolito, J. E., Kane, C. J., Kuettel, M. R., Lang, J. M., McKenney, J., Netto, G., Penson, D. F., ... Freedman-Cass, D. A. (2019). Prostate cancer, version 2.2019. JNCCN Journal of the National Comprehensive Cancer Network, 17(5), 479-505. https://doi.org/10.6004/jnccn.2019.0023

@article{a6bac757920f412c9f106341ee3092fc,

title = "Prostate cancer, version 2.2019",

abstract = "The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced disease for clinicians who treat patients with prostate cancer. The portions of the guidelines included herein focus on the roles of germline and somatic genetic testing, risk stratification with nomograms and tumor multigene molecular testing, androgen deprivation therapy, secondary hormonal therapy, chemotherapy, and immunotherapy in patients with prostate cancer.",

author = "Mohler, {James L.} and Antonarakis, {Emmanuel S.} and Armstrong, {Andrew J.} and D'Amico, {Anthony V.} and Davis, {Brian J.} and Tanya Dorff and Eastham, {James A.} and Enke, {Charles A.} and Farrington, {Thomas A.} and Higano, {Celestia S.} and Horwitz, {Eric Mark} and Michael Hurwitz and Ippolito, {Joseph E.} and Kane, {Christopher J.} and Kuettel, {Michael R.} and Lang, {Joshua M.} and Jesse McKenney and George Netto and Penson, {David F.} and Plimack, {Elizabeth R.} and Pow-Sang, {Julio M.} and Pugh, {Thomas J.} and Sylvia Richey and MacK Roach and Stan Rosenfeld and Edward Schaeffer and Ahmad Shabsigh and Small, {Eric J.} and Spratt, {Daniel E.} and Sandy Srinivas and Jonathan Tward and Shead, {Dorothy A.} and Freedman-Cass, {Deborah A.}",

year = "2019",

doi = "10.6004/jnccn.2019.0023",

language = "English",

volume = "17",

pages = "479--505",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

number = "5",

}

Mohler, JL, Antonarakis, ES, Armstrong, AJ, D'Amico, AV, Davis, BJ, Dorff, T, Eastham, JA, Enke, CA, Farrington, TA, Higano, CS, Horwitz, EM, Hurwitz, M, Ippolito, JE, Kane, CJ, Kuettel, MR, Lang, JM, McKenney, J, Netto, G, Penson, DF, Plimack, ER, Pow-Sang, JM, Pugh, TJ, Richey, S, Roach, M, Rosenfeld, S, Schaeffer, E, Shabsigh, A, Small, EJ, Spratt, DE, Srinivas, S, Tward, J, Shead, DA & Freedman-Cass, DA 2019, 'Prostate cancer, version 2.2019', JNCCN Journal of the National Comprehensive Cancer Network, vol. 17, no. 5, pp. 479-505. https://doi.org/10.6004/jnccn.2019.0023

TY - JOUR

T1 - Prostate cancer, version 2.2019

AU - Mohler, James L.

AU - Antonarakis, Emmanuel S.

AU - Armstrong, Andrew J.

AU - D'Amico, Anthony V.

AU - Davis, Brian J.

AU - Dorff, Tanya

AU - Eastham, James A.

AU - Enke, Charles A.

AU - Farrington, Thomas A.

AU - Higano, Celestia S.

AU - Horwitz, Eric Mark

AU - Hurwitz, Michael

AU - Ippolito, Joseph E.

AU - Kane, Christopher J.

AU - Kuettel, Michael R.

AU - Lang, Joshua M.

AU - McKenney, Jesse

AU - Netto, George

AU - Penson, David F.

AU - Plimack, Elizabeth R.

AU - Pow-Sang, Julio M.

AU - Pugh, Thomas J.

AU - Richey, Sylvia

AU - Roach, MacK

AU - Rosenfeld, Stan

AU - Schaeffer, Edward

AU - Shabsigh, Ahmad

AU - Small, Eric J.

AU - Spratt, Daniel E.

AU - Srinivas, Sandy

AU - Tward, Jonathan

AU - Shead, Dorothy A.

AU - Freedman-Cass, Deborah A.

PY - 2019

Y1 - 2019

N2 - The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced disease for clinicians who treat patients with prostate cancer. The portions of the guidelines included herein focus on the roles of germline and somatic genetic testing, risk stratification with nomograms and tumor multigene molecular testing, androgen deprivation therapy, secondary hormonal therapy, chemotherapy, and immunotherapy in patients with prostate cancer.

AB - The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced disease for clinicians who treat patients with prostate cancer. The portions of the guidelines included herein focus on the roles of germline and somatic genetic testing, risk stratification with nomograms and tumor multigene molecular testing, androgen deprivation therapy, secondary hormonal therapy, chemotherapy, and immunotherapy in patients with prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=85066270032&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2019.0023

DO - 10.6004/jnccn.2019.0023

M3 - Article

C2 - 31085757

AN - SCOPUS:85066270032

SN - 1540-1405

VL - 17

SP - 479

EP - 505

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 5

ER -

Prostate cancer, version 2.2019

Abstract

Access to Document

Other files and links

Fingerprint

Cite this